StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
TPSTBullishEarningsnews
High materiality8/10

Tempest Advances TPST-4003 with Senlang Collaboration; Q4 2026 Dosing Expected

Aug 13, 2026, 4:27 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive data (TPST-2003 CR rate, TPST-4003 collaboration) and clear near-term catalysts (Q4 2026 dosing, H1 2027 data) can drive upside; however, near-term funding needs and a tight cash runway may cap upside and invite dilution, creating a mixed-risk setup typical for a clinical-stage biotech during catalysts.

AI summary

What happened, with direct paths to the underlying reporting

Tempest Therapeutics unveiled Q2 2026 results and a collaboration with Hebei Senlang Biotechnology to advance TPST-4003, a CD19/BCMA dual-target in vivo CAR-T, with first patient dosing expected in Q4 2026 and initial data in H1 2027. The company also reported strong TPST-2003 interim results and appointed new board members, while cash remains tight at $0.8 million, highlighting near-term funding needs.

  • Tempest reports Q2 2026 results; updates on Senlang collaboration.
  • TPST-4003 lead candidate; first patient dosing expected Q4 2026.
  • TPST-2003 interim results: 100% CR in 15 evaluable patients; favorable safety.
  • Warrant inducement raises $2.0m; two independent directors join the board.
  • Cash on hand $0.8m as of 6/30/2026; ongoing asset acquisition costs.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event